Cleaved parp inhibitors are groups of clinical drugs that bind with the enzyme poly ADP ribose polymerase to reduce its activity in the repair mechanism of single strand DNA breaks and thus have been interred in therapeutic processes of breast cancer therapy. Parp is inactivated by caspase cleavage. To effectively understand how they work, we may need to focus on for a while on DNA breaking mechanism. During every cell cycle in the body, DNA is usually damaged and repaired. During the breaking procedure, there are special proteins that work in repairing the broken DNA. For example, BRCA1 and BRCA2 are responsible for repairing double strands DNA breaks. Through homologous recombination whereby identical molecules are accurately recombined without causing any harm, sometimes gene mutation may occur in either of the repairing proteins which in return causes errors and thus leading to breast cancer.
Parp Cleavage Inhibitors on the other hand are responsible for repairing single strand breaks in DNA whereby if the breakage persists or takes longer without repair, the errors may lead to double strand breaks which in return would be responsible for breast cancer. Cleaved Parp inhibitors have shown positive responses especially to victims with metastatic triple negative breast cancer TNBC. There are research procedures underway to demonstrate how the parp inhibitors work especially to patient who may portray signs of advanced breast cancer. As these inhibitors are solely responsible in preventing PARP from starting the repair mechanism of the DNA which is a prime objective in combating cancer cells.
Cleaved Parp Inhibitors
If PARP would not be able to repair itself from the damage of the DNA which may have occurred during the chemotherapy, the cancer causing cells will have no option but to die due to the enact nature. The outcome is not a threat to the other normal cells as the existence if BRCA function is still intact. Although there are other agents that can be induced to combat breast cancer especially the advanced refractory type, parp inhibitors still remain as primary selection of biochemists and scientists who are in every day trying to test for other uses of these enzyme inhibitors. For example, victims with advanced cases have tried out the Halaven which cripples the microtubules by reducing the activity during cell division. Although there are questions arising each day over the success of these medications, optimism seems to be building up in the case of parp inhibitors where researchers and analysts have concluded that cancer based breast tumors can be reduced by the help of these proteins.
Different patients react differently on certain medications according to their antibodies and this is the reason why research on these enzyme inhibitors has not relented not only to understand how effectively they can help in combating breast cancer but also how they could be used in treating other tumors that could lead to death. The reason why the reaction differs from patient to patient is perhaps because of the oxygen that may be within the cancer cells. For example low oxygen level cancer cells tend to be quite reactive to these enzyme inhibitors (PARP).